Drug Profile
Buparlisib - Adlai Nortye/Novartis Oncology
Alternative Names: AN-2025; BKM-120; BKM120-AAA; Buparlisib hydrochloride; NVP-BKM120Latest Information Update: 22 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis; University Hospital Tubingen
- Developer Adlai Nortye; Array BioPharma; Canadian Cancer Society Research Institute; Dana-Farber Cancer Institute; Duke University Medical Center; Emory University; Hospices Civils de Lyon; Indiana University; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); NCIC Clinical Trials Group; Novartis; Novartis Oncology; Ohio State University; Paoli-Calmettes-institute; Sarah Cannon Research Institute; Stanford University; University of California at San Francisco
- Class Amines; Antineoplastics; Morpholines; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Head and neck cancer
- Phase II Bladder cancer; Breast cancer; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Thyroid cancer; Ureteral neoplasms; Urethral cancer
- Phase I/II Colorectal cancer
- Phase I Solid tumours
- Preclinical Chronic myeloid leukaemia
- No development reported B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Mantle-cell lymphoma; Myelofibrosis; Non-small cell lung cancer; Ovarian cancer
- Discontinued Basal cell cancer; CNS cancer; Endometrial cancer; Gastrointestinal stromal tumours; Glioblastoma; Malignant melanoma; Oesophageal cancer; Prostate cancer; Renal cell carcinoma; Thymoma
Most Recent Events
- 17 Nov 2023 Adlai Nortye completes enrolment in the phase III BURAN trial for Head and neck cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in United Kingdom, Taiwan, Spain, Poland, South Korea, Japan, Italy, Hungary, Hong Kong, Germany, France, Canada, Belgium, Australia, Argentina, USA and China (PO) (NCT04338399)
- 20 Oct 2023 Efficacy data from the phase II BERIL-1 trial in Head and neck cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 08 Jun 2023 Preclinical trials in Chronic myeloid leukaemia in Switzerland (PO), before June 2023